



WHY DO SUPPLEMENT USERS TAKE SUPPLEMENTS?



**overall
health/wellness
benefits** **54%**

24% healthy aging
22% heart health

**17% help reduce
the risk of
serious illness**

PhytoActive Nutraceuticals, LLC.

Our authorized Distributor for ANKASCIN 568-R Ingredient
and Co-packer for ANKASCIN 568 Plus Finished Product

All these concerns come from

Obesity

Unhealthy Diet

Aging




Stress

Smoking



Alcohol

Physical Inactivity


Subhealth




High risk



Illness



Top 10 causes of death in high income countries



Illness



High Risk



Subhealth



These chronic diseases can increase risks of dementia



Alzheimer's disease
is the most common type of dementia

5.2
million Americans
in 2016


→ 13.8
million Americans
by 2050

That is why you need


ANKASEIN® 568-R

Active Compounds :

Monascin




Ankaflavin



- The only red yeast rice ingredient with **NO statins**, backed by the FDA-approved New Dietary Ingredient (NDI) status
- Manufactured with the patented strain and automated solid-state fermentation technology (*Monascus purpureus* NTU 568)

ANKASEIN® 568-R



Clinical Trials

FDA
APPROVED
NDI

FDA-approved
New Dietary Ingredient



Scientific Publications



NO Statin Risks



Global Patents

GMO
FREE

Non-GMO



ISO22000



HACCP




No Major Food Allergens

NBJ: Herbal supplement sales in U.S. increase 6.8% (2014)

ConsumerLab:
Fish oil does not affect LDL-C (2015)

Fish oil doses higher than 3 grams per day may increase bleeding time

8 reasons why you should choose ANKASEIN® 568-R



SPINS: RYR supplement sales in U.S. decrease 5.1% (2014)

FDA warns:
Risks of statin side effects

ConsumerLab:
Multiple RYR supplements contain a varied range of statins (2016)

Verification of Health Benefits



Animal Testing




Blood Lipids




Blood Sugar



Clinical Trials



Blood Pressure




**Memory &
Cognitive Health**


ANKASEIN® 568-R manages blood lipids

Animal Testing

Lipid plaque accumulation
in heart aorta




Normal Diet




High Cholesterol
Diet


Lipid plaque reduction



Monacolin K



Monascin




Ankaflavin

Compared with Monacolin K (lovastatin), Monascin and Ankaflavin had better effects on anti-atherosclerosis


8

Clinical Trial

Cholesterol



LDL-C







After 8 weeks of administration, cholesterol and LDL-C were significantly reduced by 11.1% and 20.4%

ANKASEIN® 568-R

manages blood sugar

Animal Testing

Insulin expression




Monascin maintained insulin expression levels against methylglyoxal-induced damage to pancreatic tissues



Clinical Trial

Fasting Blood Glucose




After 12 weeks of administration, fasting blood glucose was significantly reduced by 9.3%




ANKASEIN® 568-R manages blood pressure

Animal Testing


Short term



Long term



Diastolic blood pressure




Blood pressure was reduced in the short term and maintained in the long term


12

Animal Testing


The aorta thin sections of spontaneously hypertensive rats



Normal



Hypertensive



ANKASCIN 568-R




Irregular elastin fibers

Elastin fibers were straighter and easier to manage
blood pressure change

13

ANKASCIN®568-R supports memory and cognitive health

Animal Testing




Key risk factors ($\text{A}\beta_{1-42}$, $\text{A}\beta_{1-40}$, pTau) for Alzheimer's disease (dementia) were significantly reduced in hippocampus


Animal Testing




Amyloid Precursor Protein (APP) expression



Control



Treated with
aluminum




ANKASCIN 568-R

Another key risk factor (APP) for Alzheimer's disease was significantly reduced in hippocampus

Clinical Trial


MMSE (Mini-Mental State Examination): cognitive statuses Administration for 9 months

Placebo group



Clinical deterioration ☹

Testing group



Clinical improvement ☺


Cognitive statuses were apparently improved

SAFETY

FDA-approved New Dietary Ingredient

Clinical Trials

- Liver functions
AST, ALT, γ-GTP
- Kidney functions
Creatinine, BUN,
pH in urine



Toxicity Tests

- 90-day oral toxicity study (230X dosage)
- In vitro chromosomal aberration assay
- Micronucleus assay
- Ames test



ANKASCIN® 568-R

SPECIFICATIONS

Active compounds

Monascin ≥ 28 mg/g
Ankaflavin ≥ 9 mg/g

Aspect

Powder

Daily dosage

Blood lipids: 110 mg
Blood sugar: 220 mg
Blood pressure: 220 mg
Memory & cognitive health: 220 mg

Applicable formulation

Powder sachets, tablets, capsules



SunWay Biotech Co., LTD.

www.sunway.cc

globalservice@sunway.cc

No.139, Xing'ai Rd., Neihu District,
Taipei City 11494, Taiwan (R.O.C.)

**SupplySide®
WEST**
Las Vegas, USA
Sep 27-28 Booth #J166

PhytoActive Nutraceuticals, LLC.

Our authorized Distributor for ANKASCIN 568-R
Ingredient and Co-packer for ANKASCIN 568 Plus
Finished Product